Metabolic
Triple agonist (GLP-1, GIP, glucagon)
Retatrutide
A next-generation triple-receptor agonist studied for metabolic regulation and weight management.
- Size
- 10 mg
- Purity
- >99% (HPLC)
- Form
- Lyophilized
Per vial
$220
1
HPLC certificate included with every order
Suggested research dose: 2–12 mg weekly (titrated), subcutaneous
Discreet, temperature-controlled shipping
About this peptide
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Clinical trials have shown significant effects on weight reduction and metabolic health markers, positioning it at the frontier of metabolic peptide research.
Compliance notice
Retatrutide is sold strictly for in-vitro research and laboratory use. It is not intended for human or animal consumption. By purchasing, you acknowledge your status as a qualified research professional.